![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00092053 |
The purpose of this study is to evaluate the efficacy and safety of an investigational drug in postmenopausal women with osteoporosis.
Condition | Intervention | Phase |
---|---|---|
Postmenopausal Osteoporosis |
Drug: MK-0217, alendronate sodium/Duration of Treatment: 3 months Drug: Comparator: placebo / Duration of Treatment: 3 months |
Phase III |
Study Type: | Interventional |
Study Design: | Randomized, Double Blind (Subject, Investigator), Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Persistence of the Effect of Oral Monthly Ibandronate on Bone Reception in Postmenopausal Women in Osteoporosis |
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Responsible Party: | Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences ) |
Study ID Numbers: | 2004_007, MK0217-908 |
Study First Received: | September 21, 2004 |
Last Updated: | September 26, 2008 |
ClinicalTrials.gov Identifier: | NCT00092053 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Postmenopausal Osteoporosis |
Ibandronic acid Musculoskeletal Diseases Alendronate Osteoporosis, Postmenopausal |
Osteoporosis Bone Diseases, Metabolic Bone Diseases |
Physiological Effects of Drugs Bone Density Conservation Agents Pharmacologic Actions |